Biological agents targeting interleukin-13 for atopic dermatitis.

Andrea Chiricozzi, Niccolò Gori, Martina Maurelli, Paolo Gisondi, Giacomo Caldarola, Clara De Simone, Ketty Peris, Giampiero Girolomoni

Expert opinion on biological therapy 2022 May

filter terms:

Atopic dermatitis (AD) is a chronic inflammatory skin disease that is pathogenically driven by type-2 inflammation. Interleukin-13 (IL-13) plays a central role in AD pathogenesis, as confirmed by the clinical efficacy of agents that selectively block IL-13, although their therapeutic value and place-in-therapy are incompletely defined. This review article aimed to describe preclinical and clinical data regarding selective IL-13 inhibitors investigated in AD. In particular, we discuss the clinical outcomes obtained with lebrikizumab and tralokinumab, which are in a more advanced phase of development. Biological agents that neutralize IL-13 have demonstrated clinical benefits in treating AD with excellent safety profiles. Robust clinical evidence exists in support of tralokinumab, which underwent phase III trials, met the predefined primary endpoints, and is approaching the market. In contrast, clinical trial testing for lebrikizumab needs to be completed to fully assess its therapeutic potential.

Citation

Andrea Chiricozzi, Niccolò Gori, Martina Maurelli, Paolo Gisondi, Giacomo Caldarola, Clara De Simone, Ketty Peris, Giampiero Girolomoni. Biological agents targeting interleukin-13 for atopic dermatitis. Expert opinion on biological therapy. 2022 May;22(5):651-659